Neuromyelitis Optica
Recent clinical, regulatory, research and industry developments relating to this disease.
Estimated Brain Age in Healthy Aging and Across Multiple Neurological Disorders.
The function of astrocytes and their role in neurological diseases.
The Role of Gut Microbiome in the Pathogenesis of Multiple Sclerosis and Related Disorders.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 6 clinical trials expected to report results, the earliest in Q4 2026.
- Q4 2026A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-1)
- Q4 2026A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-2)
- Q1 2030Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)
- Q4 2030A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Remibrutinib in Patients With Secondary Progressive Multiple Sclerosis
- Q2 2031A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
Clinical MilestonesView all 16Hide
- 2026-05-19Open-Label, Randomized, Multicenter, Multiple-Dose, Active-Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label ExtensionResults posted
- 2026-02-27AGNOS: An 18-month, Open-label, Multi-Center Phase IV Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Naïve, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes.Results posted
- 2026-07-13A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Remibrutinib in Patients With Secondary Progressive Multiple SclerosisResults expected Q4 2030
- 2026-07-08Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)Results expected Q1 2030
- 2026-06-23A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple SclerosisResults expected Q2 2031
- 2026-06-18An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple SclerosisResults expected Q2 2032
- 2026-02-23A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-1)Results expected Q4 2026
- 2025-11-14A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS)Completed
- 2025-11-11An Open-Label, Prospective, Single-arm, Multi-center Study to Assess Disease Activity and Biomarkers of Neuronal Damage in Minority Patients With Relapsing Multiple Sclerosis Receiving Treatment With OcrelizumabCompleted
- 2025-11-04Open-Label Rater-Blind Randomized Multi-Center Parallel-Arm Active- Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC Monthly vs. First Line DMT - Physician's Choice in the Treatment of Newly Diagnosed RMSCompleted
- 2027-01-01A Randomized, Placebo-Controlled, Parallel-Group Study in Pediatric Subjects Ages 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 for the Treatment of Relapsing-Remitting Forms of Multiple SclerosisWithdrawn
- 2026-04-03A Phase III Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Neuromyelitis Optica Spectrum Disorders.Terminated
- 2026-01-31Open-Label Multicenter Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple SclerosisWithdrawn
- 2025-11-28Autologous Hematopoietic Stem Cell Transplant for Neuromyelitis Optica Spectrum Disorder (NMOSD)Withdrawn
- 2025-09-08A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifying Therapy (DMT)Terminated
- 2027-01-01ClinicalA Randomized, Placebo-Controlled, Parallel-Group Study in Pediatric Subjects Ages 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 for the Treatment of Relapsing-Remitting Forms of Multiple SclerosisWithdrawn
- 2026-07-13ClinicalA Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Remibrutinib in Patients With Secondary Progressive Multiple SclerosisResults expected Q4 2030
- 2026-07-08ClinicalUblituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)Results expected Q1 2030
- 2026-06-23ClinicalA Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple SclerosisResults expected Q2 2031
- 2026-06-18ClinicalAn Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple SclerosisResults expected Q2 2032
- 2026-05-19ClinicalOpen-Label, Randomized, Multicenter, Multiple-Dose, Active-Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label ExtensionResults posted
- 2026-04-03ClinicalA Phase III Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Neuromyelitis Optica Spectrum Disorders.Terminated
- 2026-02-27ClinicalAGNOS: An 18-month, Open-label, Multi-Center Phase IV Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Naïve, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes.Results posted
- 2026-02-23ClinicalA Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-1)Results expected Q4 2026
- 2026-02-23ClinicalA Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-2)Results expected Q4 2026
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Uplizna is indicated as monotherapy for the treatment of adult patients with neuromyeliti… (2022)
Approval — Satralizumab (Enspryng) is indicated as a monotherapy or in combination with immunosuppre… (2021)
Approval — Paroxysmal nocturnal haemoglobinuria (PNH)Ultomiris is indicated in the treatment of adul… (2019)
Accelerated approval — Soliris is indicated in adults and children for the treatment of: Paroxysmal nocturnal h… (2007)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Neuromyelitis Optica3
- Multiple Sclerosis2
- Aging1
- Alzheimer Disease1
- Brain1
- Central Nervous System Diseases1
- Gastrointestinal Microbiome1
- Healthy Aging1
Leading journals6
- Acta neuropathologica1
- Cells1
- Journal of magnetic resonance imaging : JMRI1
- Journal of neurology, neurosurgery, and psychiatry1
- Scientific reports1
- The European journal of neuroscience1
Leading researchers8
- Anderson MR1
- Aoki M1
- Bai Y1
- Barkhof F1
- Barnett MH1
- Bilodeau PA1
- Bobrowski-Khoury N1
- Brilot F1
Affiliations (unnormalised)6
- Beijing Tiantan Hospital1
- Boston Children's Hospital1
- Brain and Mind Centre1
- Center for Brain Research1
- Centre for Medical Image Computing1
- Children's Hospital1
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Neuromyelitis optica is a demyelinating and/or necrotizing syndrome of the central nervous system characterized by acute optic neuritis and transverse myelitis. It primarily involves the optic nerves and spinal cord and is associated with specific autoantibodies to aquaporin 4.
The grounding supports an autoimmune basis, indicated by the presence of specific autoantibodies to aquaporin 4. It also notes co-studied autoantibodies and immunoglobulin G, consistent with an antibody-mediated disease process.
The disease is linked to lesions in the optic nerves and spinal cord that are demyelinating and/or necrotizing. Aquaporin 4 is directly implicated, and astrocytes are highlighted as important because aquaporin 4 expression on astrocytes is directly related to neuromyelitis optica. The literature also points to metabolism-related aspects and broader immune and astrocytic mechanisms in related neuroinflammatory disorders.
The supplied grounding does not provide a clear treatment standard for neuromyelitis optica. Rituximab is co-studied, which suggests interest in B-cell–directed immunotherapy, but the abstracts provided do not establish it as standard of care.
AI-generated summary grounded in MeSH and 2 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
A syndrome characterized by acute OPTIC NEURITIS; MYELITIS, TRANSVERSE; demyelinating and/or necrotizing lesions in the OPTIC NERVES and SPINAL CORD; and presence of specific autoantibodies to AQUAPORIN 4.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.